Prescription drug · NDA
Forteo (teriparatide) NDC 0002-9678
Teriparatide 250 ug/mL · Injection, Solution · Subcutaneous · Eli Lilly and Company
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0002-9678-01 | 00002967801 | 1 SYRINGE in 1 CARTON (0002-9678-01) / 2.24 mL in 1 SYRINGEMarketed from Jun 3, 2025 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Forteo
- Generic name (nonproprietary)
- teriparatide
- Active ingredients
- Teriparatide — 250 ug/mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- Eli Lilly and Company
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 021318
- Marketing start
- Listing expires
- Other FDA classes
- Parathyroid Hormone (Chemical structure)
- Identifiers
- Product ID 0002-9678_d099f168-02f9-4a89-af68-f3ff6d4418e4SPL ID d099f168-02f9-4a89-af68-f3ff6d4418e4SPL set ID aae667c5-381f-4f92-93df-2ed6158d07b0RxCUI 1435115, 1435117UNII 10T9CSU89I
- Pharmacologic class
- Parathyroid Hormone Analog
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400002967801followed by a unit qualifier and the quantityPackage 00002-9678-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivale…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 021318
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Teriparatide | Teriparatide 250 ug/mL | Injection, SolutionSubcutaneous | Prasco Laboratories | 66993-495 |
| Teriparatide | Teriparatide 250 ug/mL | Injection, SolutionSubcutaneous | Prasco Laboratories | 66993-989 |
| Forteoteriparatide | Teriparatide 250 ug/mL | Injection, SolutionSubcutaneous | Eli Lilly and Company | 0002-8400 |